News, Resources, & Updates

All
  • All
  • Articles
  • Calendar
  • Compliance
  • Newsletter
  • Position Statements
  • Press Release
  • Regulatory
  • Uncategorized

In Times of Public Health Crisis, Vulnerable Consumers Look to Us for Sound Advice

Mark Land, AAHP President I have experienced many infectious disease crises thus far in my lifetime and each one was characterized by fear and uncertainty....

Member Meeting Recap: cGMPs, Draft Guidance, & More from AAHP

Eric Foxman, AAHP Secretary   AAHP held a very successful Annual Member Meeting on March 6 using a video-conferencing application.   Our keynote speaker was...

Are RCTs Really the Gold Standard of Evidence?

By Steve Mann, Director of External Regulatory Affairs, A Nelson & Co. Ltd.   Rarely do I get the opportunity to peruse the latest medical...

Online Opportunities and Responsibility

By Mark Land, AAHP President As our article on online marketing techniques shows, there’s great opportunity to increase product awareness and sales. But take caution;...

Homeopathy Consumers Are Online. Are You?

Online Marketing Techniques for Homeopathic Manufacturers Many of today’s consumers are looking for natural, safe, and effective drug products—and that means they’re turning to homeopathy....

3 Homeopathic Compliance Hot Spots to Watch

All drug products, homeopathic and allopathic alike, must be safe and effective. That means they have to be manufactured correctly, containing only the ingredients and...

How to Submit Monographs to the HPUS

FDA's Revised Draft Enforcement Document states the Agency considers only products that use substances monographed in the Homeopathic Pharmacopoeia of the United States (HPUS) as...

FDA Comment Period Extended: Help AAHP Present Manufacturers’ Voice

AAHP is preparing comments to “FDA Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry.” Initially published in December 2017, the...

AAHP’s Views on Aspects of FDA’s Revised Draft Guidance

Since 2015, the Food and Drug Administration (FDA) has been engaged in a reevaluation of Compliance Policy Guide 400.400, Conditions under Which Homeopathic Drugs May...